Aurora Sheboygan Prices – Solid Tumor Mutations by Next-Generation Sequencing: $2,960.00
Aurora Medical Center in Sheboygan County offers a specialized medical service known as Solid Tumor Mutations by Next-Generation Sequencing (NGS), priced at $2,960. This advanced diagnostic test is designed to analyze genetic mutations in solid tumors, providing crucial information that can guide personalized treatment plans for cancer patients. By examining the genetic makeup of a tumor, healthcare providers can better understand the specific characteristics of the cancer, potentially leading to more effective and targeted therapies. The cost reflects the complexity and precision of the technology used in sequencing, which is a cutting-edge tool in the field of oncology.
What is Solid Tumor Mutations by Next-Generation Sequencing? – Solid Tumor Mutations by Next-Generation Sequencing is a diagnostic test that analyzes the genetic mutations present in solid tumors to aid in the development of personalized cancer treatment plans.
Why is this test important for cancer treatment? – This test is important because it provides detailed genetic information about a tumor, allowing healthcare providers to tailor treatments that are more likely to be effective for the specific cancer type.
How does Next-Generation Sequencing work? – Next-Generation Sequencing works by rapidly sequencing large amounts of DNA, enabling the identification of genetic mutations within a tumor that may influence cancer behavior and treatment response.
What types of cancer can benefit from this test? – Many types of solid tumors, including those in the breast, lung, colon, and other organs, can benefit from this test as it helps in understanding the genetic drivers of the cancer.
Is the test covered by insurance? – Coverage for this test varies by insurance provider and plan, so it is important for patients to check with their insurance company to determine if the test is covered and what out-of-pocket costs may apply.
How long does it take to get results from the test? – The time to receive results can vary, but typically, patients can expect to receive their test results within a few weeks after the sample is collected.
Are there any risks associated with the test? – The test itself involves analyzing a sample of the tumor, which may require a biopsy, a procedure that carries standard medical risks such as infection or bleeding, but the sequencing process is non-invasive.
Who should consider getting this test? – Patients diagnosed with solid tumors who are seeking personalized treatment options may consider this test, especially if their oncologist recommends it as part of their treatment planning.
What should patients do if they have questions about the test? – Patients with questions about the test should consult their healthcare provider or oncologist, who can provide detailed information and guidance based on their individual medical needs.
